Founded in 2013, BioAscent is a leading provider of integrated drug discovery services based at the former Organon / MSD R&D site in Newhouse, Scotland, UK. Our drug discovery services include de novo assay development, target analysis and bespoke screening strategies, compound screening (including HTS), protein production, medicinal and synthetic chemistry, computational chemistry, and compound management, all with access to in-house diversity and fragment libraries. Our track record of success includes collaborations with academic groups to progress novel antibiotic drug discovery programs.